Efficient in vivo gene delivery using modified Tat peptide with cationic lipids

Area of Science:

• Biotechnology
• Gene Therapy
• Nanomedicine

Background:

• Non-viral gene vectors are crucial for gene therapy, but often face challenges with efficiency and in vivo stability.
• Previous studies demonstrated that a combination of modified HIV-1 Tat (mTat) peptide and FuGENE HD (FH) cationic lipids enhanced transfection efficiency in vitro.
• This mTat/FH combination outperformed many commercial non-viral vectors in cellular transfection.

Purpose of the Study:

• To evaluate the in vivo feasibility and efficacy of the mTat/FH non-viral vector system.
• To assess the duration and level of gene expression mediated by the mTat/FH vector in vivo.
• To investigate the immunogenicity of the mTat/FH vector in various tissues.

Main Methods:

• Plasmid DNA encoding a luciferase gene was complexed with the mTat/FH non-viral vector.
• The mTat/FH/DNA complex was administered intramuscularly to animal models.
• Luciferase gene expression levels were monitored over an extended period.
• Histological analyses were performed on muscle, liver, and kidney tissues to assess immune response.

Main Results:

• Intramuscular administration of mTat/FH/DNA resulted in significantly higher and prolonged luciferase expression compared to controls (mTat/DNA, FH/DNA, DNA alone), lasting approximately seven months.
• Histological evaluation revealed minimal to no observable immune responses in the muscles, livers, and kidneys of animals treated with the mTat/FH vector.
• The combination of mTat and FH demonstrated superior performance in vivo compared to individual components or DNA alone.

Conclusions:

• The mTat/FH non-viral vector system is a feasible and highly effective tool for in vivo gene delivery.
• This combination significantly enhances the duration and level of transgene expression.
• The low immunogenicity of the mTat/FH vector broadens its potential applications in therapeutic gene delivery and in vivo gene editing.